AXL and c‐Met Dual‐Targeting in Non‐Small Cell Lung Cancer: A Review of Small‐Molecule Inhibitors and Their Structure–Activity Relationships
Archiv der Pharmazie · 2026-03 · 359 (3)
DOI: 10.1002/ardp.70211 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, online erschienen am 20.03.2026. Verfasst von Haifeng Dong und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Jiangxi Science and Technology Normal University, Nanchang, Jiangxi, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-met, Carcinoma, Non-Small-Cell Lung, Receptor Protein-Tyrosine Kinases, Lung Neoplasms. Die Arbeit nennt 90 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the Natural Science Foundation of Jiangxi Province, the Ph.D. Start-up Fund of Science Research Project of Jiangxi Science and Technology Normal University.
Abstract (Originalsprache)
AXL and c‐Met have been identified as pivotal oncogenic factors in non‐small cell lung cancer (NSCLC), their downstream signaling pathways exhibit substantial cross‐talk, and the simultaneous inhibition of both factors has demonstrated substantial anti‐tumor efficacy. Molecular targeted therapy is characterized by its high precision and low toxicity, which confers a significant advantage in the management of NSCLC. Extensive research has explored the co‐targeting of AXL and c‐Met in both preclinical and clinical contexts, primarily emphasizing small‐molecule inhibitors. This review systematically examines the structure, function, regulatory mechanisms, and signaling pathways of AXL and c‐Met. It then highlights recent advancements in small molecule co‐targeted inhibitors of AXL and c‐Met, detailing their mechanisms of action in NSCLC treatment, and summarizes the results of relevant clinical trials. AXL and c‐Met significantly influence NSCLC cell proliferation, migration and invasion, epithelial–mesenchymal transition (EMT), and drug resistance, all of which adversely affect patient prognosis. Co‐targeting of AXL and c‐Met is considered a promising therapeutic strategy for NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Jiangxi Science and Technology Normal University, Nanchang, Jiangxi, China.
Förderung
- National Natural Science Foundation of China
- the Natural Science Foundation of Jiangxi Province
- the Ph.D. Start-up Fund of Science Research Project of Jiangxi Science and Technology Normal University
Zitieren
APA
Dong, H., Yu, M., Hong, Y., Huang, W., Zheng, P., Zhu, W., Zhang, H., & Xu, S. (2026). AXL and c‐Met Dual‐Targeting in Non‐Small Cell Lung Cancer: A Review of Small‐Molecule Inhibitors and Their Structure–Activity Relationships. Archiv der Pharmazie, 359(3). https://doi.org/10.1002/ardp.70211
Vancouver
Dong H, Yu M, Hong Y, Huang W, Zheng P, Zhu W, et al. AXL and c‐Met Dual‐Targeting in Non‐Small Cell Lung Cancer: A Review of Small‐Molecule Inhibitors and Their Structure–Activity Relationships. Archiv der Pharmazie. 2026;359(3). doi:10.1002/ardp.70211
BibTeX
@article{Dong2026,
author = {Dong, Haifeng and Yu, Mengting and Hong, Yanyun and Huang, Weijie and Zheng, Pengwu and Zhu, Wufu and Zhang, Hong and Xu, Shan},
title = {AXL and c‐Met Dual‐Targeting in Non‐Small Cell Lung Cancer: A Review of Small‐Molecule Inhibitors and Their Structure–Activity Relationships},
journal = {Archiv der Pharmazie},
year = {2026},
volume = {359},
number = {3},
doi = {10.1002/ardp.70211}
}
EUVIMED